Sickle Cell Anemia (SCA) is a group of hereditary blood disorders caused by a genetic mutation that affects hemoglobin, the molecule that delivers oxygen throughout the body via red blood cells. Hemoglobin with this mutation is referred to as HbS. HbS and normal hemoglobin (normally referred to as HbA) is a protein in red blood cells that carries oxygen from the lungs to the body’s tissues and returns carbon dioxide from the tissues back to the lungs. Hemoglobin accomplishes this function by binding and then releasing oxygen through a process by which the hemoglobin molecule changes its shape to have a high affinity for oxygen in the lungs, where oxygen is abundant, and low affinity for oxygen in the tissues, where oxygen must be released. Oxyhemoglobin, is formed in the lungs during respiration, when oxygen binds to it, while deoxygenated hemoglobin, is formed when oxygen molecules are removed from the binding site as blood flows from the lungs to the body.
ALT® is a basket of patented and proprietary technologies designed to improve the bioavailability of lipophilic materials. Normally fats and fat soluble drugs (lipophilic materials) have limited or no bioavailability. They are also subject to a phenomena called… Read MoreLearn More
ALTEMIA is our proprietary product candidate that is being developed for the treatment of sickle cell anemia. ALTEMIA consists of a complex proprietary mixture of fatty acid ethyl esters formulated using Advanced Lipid Technologies® (ALT®) specifically to address the treatment of SCA. The drug is encapsulated in a small soft gelatin capsule and intended to be taken once daily. As early as 1991, it was suggested that certain fatty acids decrease the destruction of red blood cells in mammals. It also has been found that sickle cell patients have abnormal blood fatty acids in red blood cells, white blood cells, platelets and plasma. These findings led to the hypothesis that certain fatty acids might be useful in the treatment of SCA. In 2001, a small human clinical trial showed that certain fatty acids could reduce pain episodes in sickle cell patients, perhaps by reducing activity that leads to obstructive blood clotting. Other studies have shown that certain fatty acids can increase hemoglobin levels and reduce pain episodes, VOC episodes, anemia, organ damage and other disease complications in sickle cell patients. [LEARN MORE]